Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 15;110(13):899–907. doi: 10.1136/heartjnl-2024-323867

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The treatment response of patients with Erdheim-Chester disease with cardiac involvement. (A) The cardiovascular and overall response of 21 evaluated patients who received first-line treatment. (B) The pericardial perfusion response (PER) and cardiac metabolic response (CMER) and heart response (HR) in patients who received BRAF inhibitor or not regardless of treatment lines. The size of pericardial effusion (C) and the diameter of cardiac mass (D) and the diameter change at baseline and after treatment. CR, complete response; PD, progressive disease; PR, partial response; SD. stable disease.